前列腺切除术后RestoreX的疗效:一项随机对照试验的开放标签阶段
该随机对照试验(NCT05244486)比较前列腺切除术后使用RestoreX阴茎牵引治疗(RxPTT)与不治疗5个月,随后3个月开放标签。82名男性入组,45名有9个月数据。早期治疗组在阴茎长度和勃起功能上优于未治疗组,且中断治疗后获益维持。
要点
- 前列腺切除术后1个月开始RxPTT可改善阴茎长度和勃起功能。
- 早期治疗组IIEF-EF评分变化-0.5 vs 未治疗组-8(P=0.16),阴茎长度+1.7 cm vs -0.1 cm(P<0.01)。
- 中断治疗后长度(+1.8 cm)和勃起功能(IIEF-EF评分+0)得以维持。
核心结论
- 前列腺切除术后1个月开始使用RxPTT可改善阴茎长度和勃起功能,中断治疗后获益维持。
- 若被证实,这些结果代表首个在随机对照试验中显示能改善前列腺切除术后勃起功能的术后疗法。
- 需要外部验证。
研究设计与样本
- 随机对照试验(NCT05244486)比较RxPTT与不治疗5个月,随后3个月开放标签阶段。
- 共入组82名男性(平均年龄58.6岁),45名有9个月数据。
- 按实际治疗分层:第1组=不治疗;第2组=不治疗→治疗;第3组=治疗→不治疗;第4组=治疗。
主要发现
- 第1组与第4组相比:IIEF勃起功能域评分变化-8 vs -0.5(P=0.16)。
- 第1组与第4组相比:阴茎长度变化-0.1 cm vs +1.7 cm(P<0.01)。
- 第1组与第4组相比:阴茎海绵体内注射使用率86% vs 14%(P<0.01)。
- 第1组与第4组相比:性交概况问卷(SEP)问题2阳性率50% vs 100%(P<0.01),问题3阳性率33% vs 100%(P<0.01)。
- 交叉至治疗的第2组在长度(+0.5 cm)或性功能(IIEF-EF评分-6)方面未达到与早期治疗组(第3组和第4组)相当的改善;初始治疗后交叉至不治疗的第3组长度(+1.8 cm)和勃起功能(IIEF-EF评分+0)得以维持。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report open-label phase data from a recent randomized controlled trial (RCT), after previous data from that study showed improved penile length and erectile function among post-prostatectomy men treated with Restorex penile traction therapy (RxPTT). MATERIALS AND METHODS: An RCT (NCT05244486) was performed to evaluate RxPTT vs no treatment (Tx) for 5 months, which was followed by a 3-month open-label phase. Men were stratified based on as-treated data: Group 1 = No Tx; Group 2 = No Tx → Tx; Group 3 = Tx → No Tx; Group 4 = Tx. Assessments included stretched penile length and standardized (International Index of Erectile Function [IIEF]) and non-standardized questionnaires. RESULTS: A total of 82 men were enrolled (mean age 58.6 years) with 9-month data available in 45 of the men. Baseline characteristics were similar among the cohorts. Comparing Group 1 and Group 4 (respectively), notable differences included: IIEF Erectile Function domain (IIEF-EF) score (-8 vs -0.5; P = 0.16), penile length (-0.1 vs +1.7 cm; P < 0.01), intracavernosal injection use (86% vs 14%; P < 0.01), Sexual Encounter Profile (SEP) Question 2 (50% vs 100%; P < 0.01), SEP Question 3 (33% vs 100%; P < 0.01). Men who crossed over to Tx (Group 2) failed to achieve equivalent improvements in length (+0.5 cm) or sexual function (IIEF-EF score -6) compared to men treated early (Groups 3 and 4). Those who crossed over to no treatment after initial treatment (Group 3) experienced preserved length (+1.8 cm), and erectile function (IIEF-EF score +0) despite therapy discontinuation. CONCLUSIONS: Use of RxPTT beginning 1 month post-prostatectomy results in improved penile length and erectile function, with benefits maintained after discontinuing therapy. If confirmed, these results represent the first postoperative therapy shown in a RCT to improve erectile function post-prostatectomy. External validation is warranted.
引用
- Zganjar A, Toussi A, Ziegelmann M, et al. Efficacy of RestoreX after prostatectomy: open-label phase of a randomized controlled trial. BJU Int. 2023. PMID: 37088866. doi:10.1111/bju.16033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。